Last reviewed · How we verify

Intralesional Triamcinolone

Centro Dermatológico Dr. Ladislao de la Pascua · Phase 3 active Small molecule

Triamcinolone is a corticosteroid that suppresses local inflammation and immune responses when injected directly into a lesion.

Triamcinolone is a corticosteroid that suppresses local inflammation and immune responses when injected directly into a lesion. Used for Intralesional injection for inflammatory skin conditions (e.g., keloids, hypertrophic scars, lichen planus, alopecia areata).

At a glance

Generic nameIntralesional Triamcinolone
Also known asKenalog
SponsorCentro Dermatológico Dr. Ladislao de la Pascua
Drug classCorticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Intralesional triamcinolone works by binding to glucocorticoid receptors in inflammatory cells, reducing the production of pro-inflammatory cytokines and mediators. This localized anti-inflammatory effect reduces swelling, erythema, and pruritus at the injection site while minimizing systemic exposure. The drug is commonly used for dermatologic conditions where direct tissue infiltration provides therapeutic benefit with reduced systemic side effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: